The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.
Alzheimer Disease, Agitation,Psychomotor, Depression, Anxiety, Memory Impairment, Care Giving Burden, NPS, Agitated; State, Acute Reaction to Stress, Aggression, Aggressive Outburst
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.
Clinical Trial on Agitation in Alzheimer's Dementia (CALMA)
-
ClinCloud, LLC, Maitland, Florida, United States, 32751
ClinCloud, LLC, Melbourne, Florida, United States, 32940
Global Medical Institutes Florida, LLC, Miami, Florida, United States, 33125
Neurostudies Inc., Port Charlotte, Florida, United States, 33952
BayCare Health System Inc., Saint Petersburg, Florida, United States, 33705
MedStar Franklin Square Medical Center Neurology, Baltimore, Maryland, United States, 21237
Medstar Georgetown University Hospital Neurology, Clinton, Maryland, United States, 20735
Medstar Montgomery Medical Center, Olney, Maryland, United States, 20832
Site 800, Newton, Massachusetts, United States, 02459
Dent Neurosciences Research Center, Amherst, New York, United States, 02459
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
60 Years to
ALL
No
IGC Pharma, LLC,
Dr. Saadia Shahnawaz, MD, STUDY_DIRECTOR, IGC Pharma, LLC
2025-06-30